MedTrace Logo

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

NCT05256381 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2025-11-17

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.

Conditions

Interventions

DRUG

Nanrilkefusp Alfa

Subcutaneous (SC) injection.

DRUG

Pembrolizumab

Intravenous (IV) infusion via peripheral or central venous line.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-21
Primary Completion
2024-08-31
Completion
2024-11-29
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Czechia
  • France
  • Georgia
  • Hungary
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256381 on ClinicalTrials.gov